Dexamethasone-an effective antiemetic, but is it safe? Like many 'old' drugs still in current use, dexamethasone has only slowly yielded its myriad of pharmacological actions to scientific scrutiny. In 1958, the synthesis of this new, potent, methyl-substituted corticosteroid was first reported 1 . A case series of its effectiveness in suppressing the inflammation and symptoms of rheumatoid arthritis, whilst causing minimal sodium retention or potassium loss, was published in the same year 2 . Dexamethasone was rapidly adopted for a wide range of inflammatory conditions, including use in the perioperative period to suppress surgically-induced inflammation. Observations of dexamethasone's antiemetic effects were reported 21 years later, in a letter describing the serendipitous discovery of its efficacy during cancer chemotherapy 3 . Perioperative use of dexamethasone as an antiemetic did not gain traction for a further 15 years, but has now become widespread 4 . Dexamethasone may also reduce the severity of postoperative pain and improve the quality of recovery after anaesthesia 5, 6 .
The survey by Corcoran and colleagues in this month's issue reveals just how extensive this perioperative use of dexamethasone has become 7 . Anaesthetists who responded to the survey administered dexamethasone to 46.6% of their patients to prevent postoperative nausea and vomiting (PONV). Assuming respondents were representative of current practice, this extrapolates to over one million surgical patients receiving a dose of dexamethasone in Australasia each year.
The efficacy of dexamethasone as an antiemetic is not in doubt. A recent meta-analysis included 60 randomised trials of its antiemetic effects and reported that a single dose of 4 to 10 mg given as prophylaxis reduces the incidence of PONV by about 70% 4 . What was most notable about these efficacy studies however, was not the reported antiemetic effect of the drug-indeed, it was probably not in dispute after the first couple of studies-but the lack of any detailed safety evaluation to support this extension of use for an 'old' drug.
The side-effects of long-term corticosteroid use are well-known, potentially severe and of relevance in the perioperative period. They include increased risks of thromboembolism, peptic ulceration, delayed wound healing, impaired glucose tolerance and infection. We should also be concerned about the side-effects of dexamethasone after a single dose, as it has genomic effects on inflammatory proteins that are apparent within two hours of administration and which are detectable for a week 8 .
On reviewing studies of dexamethasone as a single dose, we find few high-quality studies of side-effects. One recent review referred to 14 studies totaling 1449 patients where evidence of infection was sought and found no evidence of an increased risk of infection 6 . Indeed, 11 of these studies reported no postoperative infections at all. This suggestion of safety is supported by the reassuring review and guidelines recently published by the Society for Ambulatory Anesthesiology, in which the drug was recommended for patients at high risk of PONV 9 . However, closer inspection of the 14 studies of infection risk finds short observation periods, often restricted to in-hospital observations, or even just the first postoperative day, and a lack of adequate definitions for the side-effects sought. This contrasts with the rigorous appraisal of the efficacy outcomes in the same studies. The power of these relatively small studies to detect infrequent but important side-effects may also be limited. A recent study of major surgery in at-risk patients having noncardiac surgery reported a postoperative wound infection rate of 9% at one month 10 . On this basis, a randomised study of 1449 patients (the total number included in the systematic review referred to above 6 ) would only have had the power (80%) to detect a 50% increase in the incidence of wound infection as statistically significant (P=0.05). This large increase would be well above the threshold required to change anaesthetic protocols. The dexamethasone, light anaesthesia and tight glucose control (DeLiT) study, all interventions designed to potentially reduce the inflammatory response to surgery, also did not show an increase in complication rates including wound infections attributable to dexamethasone 11 . However, the study was abandoned for futility after 381 patients had been studied and therefore, lacked the power required to detect important side-effects.
A recent placebo-controlled study of high dose dexamethasone (1 mg/kg) in cardiac surgery, which randomised 4494 patients, provides better evidence 12 . There was no overall difference in a composite outcome measure of mortality, myocardial infarction, stroke, renal failure or respiratory failure (respiratory rate [RR]=0.83 [95% confidence interval {CI} 0.67 to 1.01], P=0.07). However, there was a decrease in reported infections (RR=0.64 [95% CI 0.54 to 0.75], P<0.001), accounted for by a decrease in pneumonia in the dexamethasone group (RR=0.26 [95% CI 0.46 to 0.69], P<0.001). The overall wound infection rate was just 1.5%, with no difference between groups (RR=1.07 [95% CI 0.66 to 1.72], P=0.79). The study indicates a possible benefit from the use of dexamethasone, but was not designed to discriminate between wound infection rates because the patients were at low risk of them.
We note that a recent case control study of patients who had developed postoperative wound infections did find an association with dexamethasone use (odds ratio=3.03 [95% CI 1.06 to 19.3], P=0.035), a result that suggests the need for a prospective safety study, rather than the pooling of evidence from efficacy studies 4, 6, 9, 12 . Dexamethasone use has also been associated with increased recurrence of cancer in some studies and increased blood glucose concentrations, the significance of which are both still the subject of debate [12] [13] [14] [15] [16] [17] .
Our profession has a responsibility to ensure that the therapies we give patients are not only effective, which dexamethasone undoubtedly is, but also backed by sound science that assures us that they are safe. The current use of dexamethasone as an antiemetic in the perioperative period is for an 'off-label' indication. A safety evaluation of dexamethasone would need to include establishing whether it has a role in causing postoperative wound infection, systemic sepsis and cancer recurrence. Its safety in diabetic patients also needs to be established. Such a safety study of dexamethasone use in the perioperative period will commence this year. The Perioperative Administration of Dexamethasone and Infection (PADDI) study, a randomised controlled trial of a single dose of dexamethasone 8 mg in 8880 patients has been endorsed by the ANZCA Clinical Trials Network and funded by the Australian National Health and Medical Research Council. This trial should provide definitive evidence of the role dexamethasone plays in patient outcome.
